Epigenome programs: a brief overview

The importance of the human epigenome in both health and disease is increasingly being realized. In the post, Dr. Lucia Altucci introduces two of the major consortia established in recent years that aim to uncover the mysteries of our epigenomic landscape.

In the last decade at least two different epigenome programs have been founded: The Epigenome Roadmap (the US based consortium) and the Blueprint Consortium (the EU based one).

The major aim of both consortia is to systematically characterize epigenomic landscapes in primary human tissues and cells. This is of an extraordinary added value in consideration of the evidence that both physiology and pathology are causally epigenetically regulated. Thus, knowing which is the ‘normal epigenome of a given cell’ can automatically define what is pathological in ‘bona fide’ human diseases.

An entire issue of Nature, entitled The Epigenome Roadmap (see articles p.317, p.331, p.337 & p.344 and Letters p.350, p.355, p.360 & p.365), studies the epigenome landscapes mainly analyzing samples taken directly from human tissues and cells, embryonic and adult, diseased and healthy. Scientists have connected these epigenome characterizations to the matching genetic data, producing reference epigenomes for tissue and cell types.

The results can be translated into a functional picture of how the epigenome regulates gene expression in the human body. Finally, although many of the functional hints still remain to be validated, having this first step may revolutionize our understanding of health and disease with the ‘functional interpretation’ of genetic information.

Dr. Lucia Altucci

Lucia Altucci is an Associate Professor at the Second University of Naples, Italy. Her research focuses on epigenetic aberrations associated with acute myeloid leukemogenesis and the therapeutic potential of epigenetic modulators in leukaemia systems.

Latest posts by Dr. Lucia Altucci (see all)

View the latest posts on the On Biology homepage